Table 2 Summary of response (n = 40)
Response | No. (%) [95% CI] | ||
|---|---|---|---|
Within 1 week before chemoradiation | 4 weeks after chemoradiation | End of treatment | |
Global | |||
Complete response | 0 | 26 (65) [48–79] | 31 (78) [62–89] |
Stage I/II | 0 | 10/14 (71) [42–92] | 11/14 (79) [49–95] |
Stage III/IV | 0 | 16/26 (62) [41–80] | 20/26 (77) [56–91] |
Partial response | 5 (13) [4–27] | 13 (33) [19–49] | 5 (13) [4–27] |
Stage I/II | 1/14 (7) [0–34] | 4/14 (29) [8–58] | 3/14 (21) [5–51] |
Stage III/IV | 4/26 (15) [4–35] | 9/26 (35) [17–56] | 2/26 (8) [1–25] |
Stable disease | 33 (83) [67–93] | 1 (3) [0–13] | 0 |
Stage I/II | 11/14 (79) [49–95] | 0 | 0 |
Stage III/IV | 22/26 (85) [65–96] | 1/26 (4) [0–20] | 0 |
Disease progression | 2 (5) [1–17] | 0 | 4 (10) [3–24] |
Stage I/II | 2/14 (14) [2–43] | 0 | 0 |
Stage III/IV | 0 | 0 | 4/26 (15) [4–35] |
Local | |||
Complete response | 0 | 27 (68) [51–81] | 34 (85) [70–94] |
Partial response | 6 (15) [6–30] | 12 (30) [17–47] | 3 (8) [2–20] |
Stable disease | 32 (80) [64–91] | 1 (3) [0–13] | 1 (2) [0–13] |
Disease progression | 2 (5) [1–17] | 0 | 2 (5) [1–17] |
